Stocks · Healthcare · Biotechnology
Protalix BioTherapeutics, Inc. PLX
$2.71 +1.12% Close, Oct 2, 2026 · AMEX · Market cap $218.3M
Strong growthHigh qualityInexpensive vs sectorLow risk
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $0.23, up 211.9% year over year.
- Operating margin widened to 28.9% from 13.3% a year earlier.
- Revenue over the last four quarters was $80.6M, up 30.1% from a year earlier, accelerating from 27.8% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 25%
- EPS growth (TTM, YoY)Top 7%
- Revenue growth, 3-year CAGRBottom 33%
- Revenue growth accelerationTop 26%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 4%
- Gross marginTop 44%
- Operating marginTop 7%
- Cash conversion (OCF / net income)Bottom 13%
- Accruals (lower is better)Bottom 8%
- Net debt / EBITDA (lower is better)Top 23%
- Interest coverTop 8%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 4%
- Free-cash-flow yieldTop 24%
- EBITDA / enterprise valueTop 5%
- Sales / enterprise valueTop 32%
- P/E vs own 5-year history (lower is better)Top 31%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 42%
- 6-month returnTop 35%
- 1-year return vs S&P 500Top 48%
- Distance from 52-week highTop 24%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 41%
- Upside to consensus price targetTop 32%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 29%
- Maximum drawdown, 3 yearsTop 29%
- Beta vs S&P 500 (lower is better)Top 32%
- Net debt / EBITDA (lower is better)Top 23%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 27.8% | 30.1% | ↑ |
| EPS growth (YoY) | 334.9% | 211.9% | ↓ |
| Gross margin | 57.5% | 69.2% | ↑ |
| Operating margin | 13.3% | 28.9% | ↑ |
| FCF margin | -5.6% | 9.5% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 30.1% | 27.8% | ↑ | Top 25% |
| EPS growth (TTM, YoY) | 211.9% | 334.9% | ↓ | Top 7% |
| Gross margin | 69.2% | 57.5% | ↑ | Top 44% |
| Operating margin | 28.9% | 13.3% | ↑ | Top 7% |
| Net margin | 23.5% | 10.1% | ↑ | — |
| Free-cash-flow margin | 9.5% | -5.6% | ↑ | — |
| Return on invested capital | 23.3% | — | Top 4% | |
| Revenue growth, 3-year CAGR | 3.5% | — | Bottom 33% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 0.52×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 8.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 2.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +44.6 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.69×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 18.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.14%
- Shareholder yield
- -0.14%
- Share count change, 1 year
- +1.6%
- Share count change, 3-year CAGR
- -0.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- -5.6%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $6.00
- Target vs current price
- +121.4%
- Analysts with a rating
- 7
- Share rating Buy or Strong Buy
- 71%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | +600.0% | +7.8% | -3.7% | +9.9% | — |
| May 13, 2026 | +2300.0% | +1.0% | -0.5% | +3.1% | +28.8% |
| Mar 18, 2026 | -800.0% | -20.8% | -25.8% | -14.7% | -26.5% |
| Nov 13, 2025 | -50.0% | -9.8% | -17.3% | -14.5% | +26.2% |
| Aug 14, 2025 | -93.3% | -5.6% | -2.5% | +8.1% | +37.9% |
| May 9, 2025 | -162.5% | -40.5% | -42.2% | -45.3% | -50.9% |
| Mar 17, 2025 | +28.6% | +9.4% | +11.2% | +7.6% | -29.5% |
| Nov 14, 2024 | -50.0% | +13.7% | +36.3% | +45.2% | +115.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | $0.05 | -$0.01 | +600.0% | $19.9M |
| May 13, 2026 | $0.22 | -$0.01 | +2300.0% | $33.8M |
| Mar 18, 2026 | -$0.07 | $0.01 | -800.0% | $9.1M |
| Nov 13, 2025 | $0.03 | $0.06 | -50.0% | $17.9M |
| Aug 14, 2025 | $0.00 | $0.03 | -93.3% | $15.7M |
| May 9, 2025 | -$0.05 | $0.08 | -162.5% | $10.1M |
| Mar 17, 2025 | $0.09 | $0.07 | +28.6% | $18.2M |
| Nov 14, 2024 | $0.03 | $0.06 | -50.0% | $18.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 11.7× | 24.6× | 20th | Top 4% |
| P/E (forward) | 11.3× | — | — | — |
| EV / EBITDA | 7.6× | — | — | Top 5% |
| EV / Sales | 2.48× | — | — | Top 32% |
| Free-cash-flow yield | 3.51% | — | — | Top 24% |
| Earnings yield | 8.53% | — | — | Top 4% |
P/E over the past five years
Range 10.5× – 110.5× since Jun 30, 2023. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +14.8%
- Earnings per share growth (TTM)
- +211.9%
- Change in P/E multiple
- -72.2%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 34
- Days above the 200-day average
- 34
- 50-day average slope (20 days)
- +6.1%
- 200-day average slope (20 days)
- +4.2%
- Distance from 50-day average
- +6.7%
- Distance from 200-day average
- +16.1%
- RSI (14)
- 54.2
- Relative volume
- 1.19×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 44.6%
- Volatility vs own 5-year history
- 14th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.80
- Correlation with S&P 500
- 0.18
- Current drawdown from 1-year high
- -14.0%
- Maximum drawdown, 3 years
- -56.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 9, 2021 | Jan 27, 2022 | -87.4% | 244 days | Not yet recovered |
| Sep 29, 2020 | Nov 5, 2020 | -19.2% | 27 days | 11 days (Nov 20, 2020) |
| Nov 24, 2020 | Dec 17, 2020 | -15.3% | 16 days | 19 days (Jan 15, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $218.3M
- P/E (TTM)
- 11.7
- EPS, diluted (TTM)
- $0.23
- Revenue (TTM)
- $80.6M
- 52-week range
- $1.60 – $3.19
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $38.4M | $47.6M | $65.5M | $53.4M | $52.7M |
| Gross profit | $22.0M | $28.0M | $42.5M | $29.1M | $25.2M |
| Operating income | -$20.5M | -$13.0M | $10.5M | $3.9M | -$5.5M |
| Net income | -$27.6M | -$14.9M | $8.3M | $2.9M | -$6.6M |
| EPS (diluted) | -$0.62 | -$0.31 | $0.10 | $0.04 | -$0.08 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.0M | $18.2M | $10.1M | $15.7M | $17.9M | $9.1M | $33.8M | $19.9M |
| Net income | $3.2M | $6.5M | -$3.6M | $164,000 | $2.4M | -$5.5M | $18.3M | $3.8M |
| EPS (diluted) | $0.03 | $0.09 | -$0.05 | $0.00 | $0.03 | -$0.07 | $0.22 | $0.05 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$10.3M | -$25.0M | -$1.3M | $8.7M | -$12.0M |
| Capital expenditure | -$1.5M | -$628,000 | -$1.1M | -$1.3M | -$1.6M |
| Free cash flow | -$11.7M | -$25.6M | -$2.5M | $7.4M | -$13.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $46.2M | $8.2M | $24.0M | $3.6M | $9.3M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $40.7M
- Total assets
- $110.3M
- Total liabilities
- $38.9M
- Total debt
- $9.2M
- Net debt
- -$18.2M
- Shareholders’ equity
- $71.4M
As of Jun 30, 2026 (filed Aug 12, 2026).
Short interest
- Shares sold short
- 2,877,740
- Days to cover
- 3.82
- Change vs previous report
- -9.1%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Dec 20, 2019
- 1-for-10
- Jan 3, 2007
- 1-for-10